Search - tctmd.com

Displaying 61 - 80 of 84

Sort: Relevancy | Date

Presentation TCT 2014

YES: CHAMPION PHOENIX was Convincing!

Presenter: Deepak L. Bhatt

September 14, 2014

Presentation TCT 2014

TCT 406: Renal Artery Trauma Induced by Four Different Renal Denervation Systems: A Multimodality Intraarterial Imaging Study

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Antonios Karanasos

September 14, 2014

Presentation TCT 2014

Updates and Status of the Cordis Renlane Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Felix Mahfoud

September 14, 2014

Presentation TCT 2014

Updates and Status of the ReCor Paradise Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Thomas Zeller

September 14, 2014

Presentation TCT 2014

Updates and Status of the St. Jude EnligHTN Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

Presentation TCT 2014

Updates and Status of the Boston Scientific Vessix Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Ajay J. Kirtane

September 14, 2014

Presentation TCT 2014

From SYMPLICITY HTN-1 to the Global SYMPLICITY Registry and Beyond: Updates from and Status of the SYMPLICITY Clinical Trial Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Michael Boehm

September 14, 2014

Presentation TCT 2014

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, John Flack

September 14, 2014

Presentation TCT 2014

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

$SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups$

Presentation TCT 2014

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

Presenter: Patrick W. Serruys, Deepak L. Bhatt

September 13, 2014

Presentation TCT 2013

The Case for Intravenous Cangrelor as the Preferred ADP Antagonist to Support Primary PCI

Presenter: Deepak Bhatt

October 30, 2013

Presentation TCT 2013

Important Lessons from SIMPLICITY HTN-3 (Inclusion Criteria, Site Selection, and Study Endpoints): What I Would Do Differently Next Time?

Presenter: Deepak Bhatt

October 30, 2013

Presentation

Welcome and Introductions/Pre-test

Presenter: Deepak Bhatt

October 29, 2013

Presentation

Perspectives in Individualized Antiplatelet Therapy: Comorbidities and Characteristics

Presenter: Deepak Bhatt

October 29, 2013

Presentation

CHAMPION PHOENIX

Presenter: Deepak L. Bhatt

March 09, 2013

$SIMPLICITY 3 Update: Issues with Enrolling Refractory Patients$

Presentation TCT 2012

SIMPLICITY 3 Update: Issues with Enrolling Refractory Patients

Presenter: Deepak Bhatt

October 25, 2012

Presentation TCT 2012

What's Known and Not Known About Renal Denervation for Hypertension: Critical Appraisal of the Clinical Data

Presenter: Deepak Bhatt

October 24, 2012

Presentation TCT 2012

Sham Trials Are Burdensome and Introduce Their Own Errors!

Presenter: Deepak Bhatt

October 24, 2012

Presentation TCT 2012

State-of-the-Field Keynote: The Next Challenge: Improving Technical Efficiency and Biological Response (Nonresponders)

Presenter: Deepak Bhatt

October 23, 2012

Presentation TCT 2012

Hypertension: Renal Denervation

Presenter: Deepak Bhatt

October 23, 2012

Advertisement

YES: CHAMPION PHOENIX was Convincing!

TCT 406: Renal Artery Trauma Induced by Four Different Renal Denervation Systems: A Multimodality Intraarterial Imaging Study

Updates and Status of the Cordis Renlane Program

Updates and Status of the ReCor Paradise Program

Updates and Status of the St. Jude EnligHTN Program

Updates and Status of the Boston Scientific Vessix Program

From SYMPLICITY HTN-1 to the Global SYMPLICITY Registry and Beyond: Updates from and Status of the SYMPLICITY Clinical Trial Program

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

The Case for Intravenous Cangrelor as the Preferred ADP Antagonist to Support Primary PCI

Important Lessons from SIMPLICITY HTN-3 (Inclusion Criteria, Site Selection, and Study Endpoints): What I Would Do Differently Next Time?

Welcome and Introductions/Pre-test

Perspectives in Individualized Antiplatelet Therapy: Comorbidities and Characteristics

CHAMPION PHOENIX

SIMPLICITY 3 Update: Issues with Enrolling Refractory Patients

What's Known and Not Known About Renal Denervation for Hypertension: Critical Appraisal of the Clinical Data

Sham Trials Are Burdensome and Introduce Their Own Errors!

State-of-the-Field Keynote: The Next Challenge: Improving Technical Efficiency and Biological Response (Nonresponders)

Hypertension: Renal Denervation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content